Health locus of control and the sense of self-efficacy in patients with systolic heart failure: a pilot study

Agnieszka Rydlewska1,2
Justyna Krzysztofik3
Julia Libergal3
Agata Rybak3
Waldemar Banasiak1
Piotr Ponikowski1,2
Ewa A Jankowska1,2
1Centre for Heart Diseases, Department of Cardiology, Military Hospital, Wroclaw, Poland; 2Department of Heart Diseases, Wroclaw Medical University, Wroclaw Poland; 3Student’s Scientific Organization, Laboratory for Applied Research on Cardiovascular System, Wroclaw Medical University, Wroclaw, Poland

Background: Treatment of heart failure (HF) requires the lifelong adherence to medical self-care regimes. The objective of this study was to examine health-control beliefs and the sense of self-efficacy (psychological features particularly important for efficient compliance among patients suffering from chronic diseases) in patients with systolic HF in relation to clinical status and depressive symptoms.

Subjects and methods: Sixty-six consecutive patients with chronic systolic HF, hospitalized in the Centre for Heart Diseases, Military Hospital (94% men, age: 61 ± 11 years, ischemic etiology: 63%, left ventricular ejection fraction: 32% ± 12%), filled in (during their hospital stay): (1) the Multidimensional Health Locus of Control Scale measuring three possible localizations of health control: “internality” (ie, the belief that health status depends only on personal decisions and behaviors); “powerful others externality” (PHLC subscale) ie, the conviction that health depends on “powerful people” such as doctors, family members, close friends), and “chance externality” (ie, belief that health status is determined by chance, fate, or luck), and (2) the Generalized Self-Efficacy Scale. The results obtained by HF patients were compared to those reported by patients with other chronic diseases and healthy subjects.

Results: In patients with HF, internality was similar to values obtained by patients with diabetes, men after myocardial infarction, and women after mastectomy; and was lower than in healthy subjects. Powerful others externality was more pronounced in patients with HF as compared to other groups of patients and healthy people. Only women after mastectomy had higher scores of PHLC. In patients with HF, chance externality was similar to values reported in patients with renal failure, men after myocardial infarction, and women after mastectomy; and was less pronounced than in healthy subjects. The majority (77%) of patients with HF were characterized by a high sense of self-efficacy (> the 7th sten score), having the highest sense of self-efficacy among patients with other chronic diseases and healthy controls. Higher internality was accompanied by higher sense of self-efficacy (P < 0.05) in patients with HF. Subjects with high plasma N-terminal pro-B type natriuretic peptide (reflecting the disease severity) had the least pronounced internality (P < 0.05), whereas those with more advance depressive symptoms had the lower sense of self-efficacy (P = < 0.05).

Conclusion: Patients with systolic HF demonstrate a conviction that other people, including physicians, have a large influence on their health status, and at the same time are aware of the efficacy of their own activities in coping with the disease. Such a configuration of psychological features seems to be beneficial in the context of the developing modern strategies, which due to the improved cooperation between the physicians and the patients could enhance the compliance in patients with HF.

Keywords: health locus of control, self-efficacy, heart failure, compliance, depressive symptoms
Introduction
Heart failure (HF) is a chronic, long-lasting condition, the progression of which can be partially postponed, but not stopped. The treatment strategy in HF requires the lifelong adherence to medical self-care regimes, such as: medications, dietary sodium restrictions, and self-monitoring (eg, daily weight measurements). Although high compliance improves outcomes in HF, it is difficult to maintain compliance in a long-term perspective. The reasons for noncompliance have not been clearly established; however, there are premises arising from the studies performed in patients with other chronic diseases that noncompliance may be related to the psychological features of patients and there are suggestions that psychological interventions could improve compliance among HF patients. In this context, two psychological features seem to be of crucial importance: ie, health locus of control and the sense of self-efficacy.

Health locus of control refers to the individual’s beliefs regarding the control of health, whereas the sense of self-efficacy reflects the individual’s belief in his/her own skills to plan and perform certain activities to attain particular aims. None of these features have been investigated in patients with HF. Thus, the objective of this study was to examine the health control beliefs and the sense of self-efficacy in patients with stable systolic HF, also in the context of their clinical status and depressive symptoms.

Subjects and methods
Study population
We examined patients with systolic HF hospitalized in the Centre for Heart Diseases, Military Hospital (Wroclaw, Poland). There were the following inclusion criteria for the study: (1) a 6-month documented history of HF (New York Heart Association [NYHA] I–III classes); (2) clinical stability with unchanged medications for 3 months preceding the study; and (3) left ventricular ejection fraction < 45% as assessed by echocardiography.

Exclusion criteria comprised: (1) HF decompensation within 3 months preceding the study; (2) acute coronary syndrome and/or coronary revascularization during the 6 months preceding the study; and (3) any psychiatric abnormalities and associated therapy either at the time of examination or in the past.

The study was approved by the local ethics committee. All subjects gave written informed consent. The study was conducted in accordance with the Declaration of Helsinki.

Study protocol
Each patient underwent a physical examination with routine laboratory tests and standard transthoracic echocardiography. Plasma N-terminal pro-B type natriuretic peptide ([NT-proBNP] pg/mL) was measured using electrochemiluminescence on the Elecsys 1010/2010 System (Roche Diagnostics GmbH, Mannheim, Germany). Renal function was assessed using the estimated glomerular filtration rate ([GFR] mL/minute/1.73 m²), calculated from the Modification of Diet in Renal Disease equation. Serum high-sensitive C-reactive protein (hsCRP, mg/L) was assessed using immunonephelometry (analyser no BN II, Dade Behring, Siemens AG, Munich, Germany). Afterwards, each patient completed psychological questionnaires assessing.

1. the health locus of control, and
2. the sense of self-efficacy.

Health locus of control (ie, the set of personal beliefs regarding the control of individual health status), was assessed using the Polish version of the Multidimensional Health Locus of Control Scale ([MHLC] forms A and B), originally proposed by Wallston et al and adopted by Juczynski in 1999. MHLC measures three possible localizations of health control: internal localization, called “internality” (internal locus of control, measured by a subscale named IHLC) and two external localizations called “powerful others externality” (measured by a subscale named PHLC) and “chance externality” (measured by a subscale named CHLC).

Patients with high internality (those having high scores on the IHLC subscale) believe that their health status depends only on their own behaviors.

Patients with high powerful others externality (expressed as high scores on the PHLC subscale) are convinced that their individual health status is the consequence of the actions performed by powerful people, eg, doctors, family members, friends.

Patients with high chance externality (expressed as high scores on the CHLC subscale) believe that mainly chance, fate, or luck determine their health status.

Each subscale is composed of six items. The answers for each item are expressed using a 6-point Likert scale, where the lowest score (1) means “strongly disagree,” and the highest score (6) means “strongly agree.” Thus, it is possible to obtain from 6 to 36 points in each subscale. The initial publication regarding these scales established the fact that they are internally consistent and concurrently valid. Patients with HF examined in the present study were compared with
Results

Sixty-six patients with systolic HF were enrolled in the study. The majority of them were males, classified in the NYHA I–II classes, and received standard pharmacotherapy (Table 1). A BDI score ≥ 16 was recorded in approximately 40% of the examined subjects.

Health locus of control and the sense of self-efficacy in patients with HF

The distribution of MHLC scores recorded in patients with HF was presented in Table 2. The most pronounced localization of health control in examined patients with HF were powerful others externality and internality. Low, moderate, and high

Table 1 Baseline characteristics of 66 examined patients with systolic heart failure

<table>
<thead>
<tr>
<th>Variables</th>
<th>Patients with HF (n = 66)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>61 ± 11</td>
</tr>
<tr>
<td>Men (n [%])</td>
<td>60 (91%)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.5 ± 4.1</td>
</tr>
<tr>
<td>Ischemic HF etiology (n [%])</td>
<td>63 (95%)</td>
</tr>
<tr>
<td>NYHA classes I/II/III (n [%])</td>
<td>11 (17%)/39 (59%)/16 (24%)</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>32 ± 12</td>
</tr>
<tr>
<td>NT-proBNP (pg/mL)</td>
<td>1251 (591–3923)</td>
</tr>
<tr>
<td>Hypertension (n [%])</td>
<td>31 (47%)</td>
</tr>
<tr>
<td>DM (n [%])</td>
<td>23 (35%)</td>
</tr>
<tr>
<td>Hemoglobin (g/dL)</td>
<td>18.8 ± 1.7</td>
</tr>
<tr>
<td>eGFR-MDRD (mL/minute/1.73 m²)</td>
<td>71.2 ± 22.7</td>
</tr>
<tr>
<td>Sodium (mmol/L)</td>
<td>140 ± 3</td>
</tr>
<tr>
<td>hsCRP (mg/L)</td>
<td>3.34 (1.50–9.23)</td>
</tr>
<tr>
<td>BDI score</td>
<td>13 ± 9</td>
</tr>
<tr>
<td>BDI-scores: ≤ 10/11–15/16 (n [%])</td>
<td>25 (38%)/13 (20%)/28 (42%)</td>
</tr>
<tr>
<td>BDI score for C-A</td>
<td>6 ± 6</td>
</tr>
<tr>
<td>BDI score for S</td>
<td>8 ± 4</td>
</tr>
</tbody>
</table>

Treatment

ACEI and/or ARB (n [%]) 50 (75%)
Beta-blocker (n [%]) 57 (86%)
Aldosterone antagonist (n [%]) 34 (51%)
Digoxin (n [%]) 12 (18%)
Loop diuretic (n [%]) 25 (38%)
Thiazide diuretic (n [%]) 21 (32%)
Statin (n [%]) 48 (73%)
ASA (n [%]) 35 (52%)

Note: Results are presented as a mean ± standard deviation, a median with lower and upper quartiles, or a number with a percentage.

Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor antagonist; ASA, acetylsalicylic acid; BDI, Beck Depression Inventory; BMI, body mass index; (C-A), BDI subscale for cognitive and affective depressive symptoms; DM, diabetes mellitus; eGFR-MDRD, estimated glomerular filtration rate calculated using the MDRD formula; HF, heart failure; hsCRP, high sensitivity C-reactive protein; LVEF, left ventricular ejection fraction; MDRD, Modification of Diet in Renal Disease; NT-proBNP, N-terminal pro-B type natriuretic peptide; NYHA, New York Heart Association; S, BDI subscale for somatic symptoms of depression.
Table 2 Distribution of scores in three subscales of the Multidimensional Health Location of Control scale in 66 patients with systolic heart failure

<table>
<thead>
<tr>
<th>MHLC subscales</th>
<th>Scores</th>
<th>Min</th>
<th>−1 SD</th>
<th>Mean</th>
<th>+1 SD</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>iHLC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHLC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHLC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CHLC, a subscale measuring external location of health control focused on the role of luck; iHLC, a subscale measuring an internal location of health control; max, maximum value; MHLC, Multiple Health Control Localization scale; min, minimum value; PHLC, a subscale measuring external location of health control focused on the role of other, powerful people; SD, standard deviation of a mean.

As far as we are aware, this is the first report providing evidence on the localization of health control and the sense of self-efficacy in patients with HF compared to patients with other chronic diseases and healthy subjects.

The magnitude of internality was inversely related to plasma NT-proBNP in patients with HF (r = −0.26, P = 0.04) and somatic depressive symptoms (r = −0.28, P = 0.03).

There were no other relationships between health control localization, the sense of self-efficacy, and any clinical variable (all P > 0.2).

Discussion

As far as we are aware, this is the first report providing evidence on the localization of health control and the sense of self-efficacy in patients with HF compared to patients with other chronic diseases and healthy subjects.

Powerful others externality was more pronounced in patients with HF as compared to patients with other chronic diseases and healthy subjects (all P < 0.05) (Table 3). Chance externality was similar in patients with chronic diseases and healthy subjects (all P > 0.2). Patients with HF had higher PHLC scores (P < 0.05) compared to the other groups of patients with chronic diseases and healthy controls. Patients with systolic HF with the higher sense of self-efficacy had also more pronounced internality (r = 0.29, P = 0.02).

Associations between health control and self-efficacy, and depressive symptoms of patients with HF

There were no other relationships between health control localization, the sense of self-efficacy, and any clinical variable (all P > 0.2).
The localization of health control is important in the context of coping with chronic diseases. Internality and powerful others externality are positively related to drug compliance in patients with schizophrenia,\(^9\) internality predicts better adherence to treatment recommendations among patients with chronic pain,\(^10\) as well as among injured athletes.\(^11\) High self-efficacy is related to self-care behaviors in kidney transplant recipients,\(^7\) in patients with diabetes,\(^18\) and also in healthy people.\(^19\)

It seems that patients with HF are unique with regard to these two psychological features as compared to the other groups of patients with chronic diseases living in Poland. The most pronounced localization of health control in examined patients with HF was powerful others externality, which may suggest that they could potentially seriously take into consideration medical advice from physicians. The magnitude of internality was relatively high, indicating that they could also take substantial responsibility for their health status. Most importantly, patients with HF were characterized by much higher sense of self-efficacy as compared to the other groups of patients.\(^8\) Both features should be taken into consideration while planning modern strategies aiming to improve self-care and compliance in patients with HF.

In the present study, we found no associations between the health-control localization, the sense of self-efficacy, and clinical parameters, in spite of the inverse relationship between plasma NT-proBNP (a parameter which reflects the severity of the disease; higher NT-proBNP is characteristic of more advanced HF) and internality. This may be related to the common awareness in contemporary societies that the most important causes of cardiovascular diseases (eg, HF) are the consequence of unhealthy lifestyles,\(^10\) which is related to the common conscience of the individual responsibility for one’s health status.

Depressive symptoms are common in patients with HF, and are related to the severity of the disease.\(^12\) In the present study, the higher sense of self-efficacy was accompanied by less marked depressive symptoms in patients with HF, which is consistent with previous studies in patients with chronic diseases\(^18,21\) as well as among healthy people.\(^22\) Importantly, the sense of self-efficacy can be a mediator in the reaction to strong stressors (eg, chronic disease and related debilitating symptoms, such as dyspnea in HF) and the occurrence of depressive symptoms.\(^23\) It has been demonstrated that the increase in self-efficacy due to a modeling intervention in patients with HF was followed by a significant improvement in clinical status (eg, a reduction of exercise intolerance expressed by an increased peak oxygen consumption).\(^24\)

**Limitations**

We are aware that our study has some limitations related to the applied methodology, which need to be acknowledged.

Firstly, our results may be affected by selection bias, as there is no doubt that there are differences in psychological features between those who agree and disagree to participate in this kind of study, and we will never be able to familiarize

---

**Table 3** Mean values of MHLC and GSES scores in patients with systolic heart failure, patients with other chronic diseases, and healthy subjects

<table>
<thead>
<tr>
<th>Variables</th>
<th>Patients with HF n = 66</th>
<th>Patients with other chronic diseases*</th>
<th>Healthy subjects*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patients with DM n = 70</td>
<td>Patients with renal failure n = 31</td>
<td>Men after MI n = 42</td>
</tr>
<tr>
<td>IHLC (points)</td>
<td>26 ± 5</td>
<td>26 ± 6</td>
<td>24 ± 3*</td>
</tr>
<tr>
<td>CHLC (points)</td>
<td>29 ± 5</td>
<td>26 ± 7*</td>
<td>25 ± 4*</td>
</tr>
<tr>
<td>GSES (points)</td>
<td>22 ± 6</td>
<td>20 ± 7*</td>
<td>22 ± 5</td>
</tr>
<tr>
<td></td>
<td>32 ± 4</td>
<td>28 ± 5*</td>
<td>27 ± 5*</td>
</tr>
</tbody>
</table>

*Notes: Results are presented as mean ± standard deviations. *P < 0.05 – the particular group versus patients with systolic HF.

**Abbreviations:** CHLC, a subscale measuring external location of health control focused on the role of luck; DM, diabetes mellitus; GSES, Generalized Self-Efficacy Scale; HF, heart failure; IHLC, a subscale measuring an internal location of health control; MHLC, Multiple Health Control Localization scale; MI, myocardial infarction; PHLC, a subscale measuring external location of health control focused on the role of other, powerful people.
ourselves with the psychological features of subjects who refuse to fill in psychological questionnaires. Moreover, the study was performed among hospitalized patients. It is likely that the results obtained among outpatient clinic patients with HF, who were not included in the present study, would be different. As a result, our findings cannot be generalized beyond the studied group.

Secondly, all applied questionnaires are typical self-reported measures, which are related with a potential risk of misstatement.

Thirdly, the present study constitutes a preliminary report regarding two psychological features that may be related to self-care and compliance with medical regimes in patients with HF. We did not analyze an actual rate of compliance among examined patients, and undoubtedly such analyses should be performed as the continuation of our project.

Conclusion

Patients with systolic HF demonstrate a conviction that other people, including physicians, have a large influence on their health status, and at the same time are aware of the efficacy of their own activities in coping with the disease. Such a configuration of psychological features seems to be beneficial in the context of the developing modern strategies, which (due to the improved cooperation between the physicians and the patients) could enhance compliance in patients with HF.

Acknowledgments

The project was funded by The National Science Centre, Cracow, Poland, grant number 2011/03/N/NZS/00243, and by Wroclaw Medical University, Wroclaw, Poland (statutory activities of Laboratory for Applied Research on Cardiovascular System in 2012, ST-722).

Disclosure

The authors report no conflicts of interest in this work.

References

1. McMurray JJ, Adamopoulos S, Anker SD, et al; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803–869.